5 Key Takeaways

• 1

  The FDA has cleared the Elecsys Phospho-Tau (217P) Plasma blood test for identifying amyloid pathology in Alzheimer's disease.

• 2

  The test is intended for patients aged 55 and older with cognitive decline symptoms and provides classifications of positive, intermediate, or negative.

• 3

  Elecsys pTau217 was developed in collaboration with Eli Lilly and Company and shows high concordance with amyloid PET imaging results.

• 4

  The assay can be integrated into existing laboratory workflows on Roche cobas instruments without additional equipment.

• 5

  The test results should be used alongside other clinical information and are not established for predicting future dementia or tracking treatment responses.